@alexonline888 @alifewithoutus @CreepyOrg Magnesium isn't a cure. Studies proved this. However, some evidence does show about 7 out of 10 people with Raynauds have Magnesium deficiencies. Better, and working along the same lines, though no guarantee, is p
RT @Janetbirdope: #ClinicalPearl If treating #Raynaud’s 2nd to CTD Rx #scleroderma nifedipine or other dihydropyridines may ⬇️number of RP…
RT @Janetbirdope: #ClinicalPearl If treating #Raynaud’s 2nd to CTD Rx #scleroderma nifedipine or other dihydropyridines may ⬇️number of RP…
RT @Janetbirdope: #ClinicalPearl If treating #Raynaud’s 2nd to CTD Rx #scleroderma nifedipine or other dihydropyridines may ⬇️number of RP…
RT @Janetbirdope: #ClinicalPearl If treating #Raynaud’s 2nd to CTD Rx #scleroderma nifedipine or other dihydropyridines may ⬇️number of RP…
RT @Janetbirdope: #ClinicalPearl If treating #Raynaud’s 2nd to CTD Rx #scleroderma nifedipine or other dihydropyridines may ⬇️number of RP…
#ClinicalPearl If treating #Raynaud’s 2nd to CTD Rx #scleroderma nifedipine or other dihydropyridines may ⬇️number of RP attacks by 30%, maybe no diff in severity of existing attacks. Dose response where Nifedipine 60 to 90 mg/d is better than 10-30mg. ht
RT @Actual_clinica: Bloqueadores de los canales de calcio para el fenómeno de Raynaud primario y secundario Cochrane https://t.co/pXQ8Y0no…
RT @Actual_clinica: Bloqueadores de los canales de calcio para el fenómeno de Raynaud primario y secundario Cochrane https://t.co/pXQ8Y0no…
Bloqueadores de los canales de calcio para el fenómeno de Raynaud primario y secundario Cochrane https://t.co/pXQ8Y0noY8
Inhibiteurs des canaux calciques pour le phénomène de Raynaud primitif et secondaire https://t.co/9bS5lv7DrN
Calcium channel blockers for primary and secondary Raynaud's phenomenon. https://t.co/E1fu7dbIba
RT @Epocrates: Calcium channel blockers for Raynaud phenomenon https://t.co/MJB8V7d9Qt via @cochranecollab https://t.co/Mdp0YvPjV1
Calcium channel blockers for Raynaud phenomenon https://t.co/MJB8V7d9Qt via @cochranecollab https://t.co/Mdp0YvPjV1
RT @DMGParisV: #LectureDeLaSemaine Quelle est l'efficacité des inhibiteurs calciques dans le syndrome de Raynaud? via Cochrane... https://t…
#LectureDeLaSemaine Quelle est l'efficacité des inhibiteurs calciques dans le syndrome de Raynaud? via Cochrane... https://t.co/zndh0uIn1Z
RT @CochraneLibrary: Calcium channel blockers (especially the dihydropyridine class) may be useful in reducing the frequency, duration, sev…
Calcium channel blockers for treatment of patients with Raynaud’s phenomenon https://t.co/AUSa7ZWwiD
RT @CochraneLibrary: Calcium channel blockers (especially the dihydropyridine class) may be useful in reducing the frequency, duration, sev…
RT @CochraneLibrary: Calcium channel blockers (especially the dihydropyridine class) may be useful in reducing the frequency, duration, sev…
Calcium channel blockers (especially the dihydropyridine class) may be useful in reducing the frequency, duration, severity of attacks, #pain, and disability associated with #Raynaud's phenomenon: https://t.co/rCxq8Qhnxv #CCBs
RT @CochraneUK: Calcium channel blockers (especially the dihydropyridine class) may be useful in reducing the frequency, duration, severity…
RT @CochraneUK: Calcium channel blockers (especially the dihydropyridine class) may be useful in reducing the frequency, duration, severity…
RT @rincondesisifo: (Cochrane) Seguridad y eficacia de los antagonistas del calcio dihidropiridínicos en la enfermedad de Raynaud https://t…
RT @CochraneUK: Calcium channel blockers for treating Raynaud's phenomenon. Here's the latest #CochraneEvidence: https://t.co/YPENOwLnCZ ht…
RT @rincondesisifo: (Cochrane) Seguridad y eficacia de los antagonistas del calcio dihidropiridínicos en la enfermedad de Raynaud https://t…
RT @rincondesisifo: (Cochrane) Seguridad y eficacia de los antagonistas del calcio dihidropiridínicos en la enfermedad de Raynaud https://t…
RT @rincondesisifo: (Cochrane) Seguridad y eficacia de los antagonistas del calcio dihidropiridínicos en la enfermedad de Raynaud https://t…
RT @CochraneUK: Calcium channel blockers for treating Raynaud's phenomenon. Here's the latest #CochraneEvidence: https://t.co/YPENOwLnCZ ht…
RT @CochraneUK: Calcium channel blockers for treating Raynaud's phenomenon. Here's the latest #CochraneEvidence: https://t.co/YPENOwLnCZ ht…
RT @rincondesisifo: (Cochrane) Seguridad y eficacia de los antagonistas del calcio dihidropiridínicos en la enfermedad de Raynaud https://t…
RT @CochraneUK: Calcium channel blockers for treating Raynaud's phenomenon. Here's the latest #CochraneEvidence: https://t.co/YPENOwLnCZ ht…
RT @CochraneUK: Calcium channel blockers for treating Raynaud's phenomenon. Here's the latest #CochraneEvidence: https://t.co/YPENOwLnCZ ht…
RT @CochraneUK: Calcium channel blockers for treating Raynaud's phenomenon. The latest #CochraneEvidence: https://t.co/3vL5rvXn5J https://t…
RT @CochraneUK: Calcium channel blockers for treating Raynaud's phenomenon. Here's the latest #CochraneEvidence: https://t.co/YPENOwLnCZ ht…
RT @CochraneUK: Calcium channel blockers for treating Raynaud's phenomenon. Here's the latest #CochraneEvidence: https://t.co/YPENOwLnCZ ht…
RT @rincondesisifo: (Cochrane) Seguridad y eficacia de los antagonistas del calcio dihidropiridínicos en la enfermedad de Raynaud https://t…
RT @rincondesisifo: (Cochrane) Seguridad y eficacia de los antagonistas del calcio dihidropiridínicos en la enfermedad de Raynaud https://t…
(Cochrane) Seguridad y eficacia de los antagonistas del calcio dihidropiridínicos en la enfermedad de Raynaud https://t.co/zUcOmXHhjB Evidencia de calidad moderada
Vorbeugung und Therapie des Raynaud Syndroms. Helfen Kalziumkanalblocker (Kalziumantagonisten) mehr beim primären als beim sekundären Raynaud? https://t.co/pgp72e2BG6
Calcium channel blockers for treatment of patients with Raynaud’s phenomenon https://t.co/kZ0W5wly8x
Calcium channel blockers and Raynaud's phenomenon https://t.co/oBlLhmNkuB
Calcium channel blockers for primary and secondary Raynaud's phenomenon. https://t.co/MggzM3mM59